ABS-752
ABS-752 is an orally active prodrug targeting CRBN-modulating molecular glue with selectivity in protein degradation. ABS-752 preferentially degrades GSPT1 and induces cytotoxicity through this degradation, while it also degrades NEK7, SALL4 and CK1α, with weaker degradation potency against CK1α. As a prodrug, ABS-752 requires metabolic activation to ABT-002 to form the active complex; VAP-1 mediates its conversion to an aldehyde intermediate. ABS-752 induces cell death, reduces cell viability, and exhibits antitumor activity, leading to regression and inhibition of tumor growth. ABS-752 shows no cytotoxicity in primary human hepatocytes. ABS-752 can be used in the research of hepatocellular carcinoma.
For research use only. We do not sell to patients.
- CAS No.: 2761170-84-5
- Formula: C14H14FN3O3
- Molecular Weight:291.28
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Eukaryotic Release Factor (eRF) Isoforms
More
Biological Activity
Description
IC50 & Target
|
eRF3a/GSPT1 1 nM (DC50, Hep3B, 24 h) |
NEK7 9 nM (DC50, Hep3B, 24 h) |
In Vitro
ABS-752 (72 h) exerts cytotoxic/cytostatic activity in 13 of 19 tested HCC cell lines, reducing viability by at least 50%[1].
ABS-752 (1-50 μM; 72 h) reduces viability in wild-type Hep3B cells, but has no effect on Hep3B GSPT1G575N cells, demonstrating that GSPT1 degradation drives its cytotoxic activity[1].
ABS-752 (0.1 nM-30 μM; 72 h) has viability-reducing activity in Hep3B cells that is dependent on VAP-1[1].
ABS-752 (6 h, 24 h) potently degrades GSPT1 (DC50=1 nM at 24 h), NEK7 (DC50=9 nM at 24 h), CK1α (DC50=35 nM at 24 h) in Hep3B cells, and SALL4 (DC50=40 nM at 24 h) in Kelly cells, with GSPT1 as the primary target showing near-complete degradation at early time points[1].
ABS-752 (0.1 μM; 6 h) preferentially degrades GSPT1, with greater degradation of NEK7 than CK1α[1].
ABS-752 (1-10 μM) does not form a biochemical ternary complex with CRBN and GSPT1, NEK7, CK1α, or IKZF1, but shows recruitment activity with SALL4[1].
ABS-752 (10 μM; 0-20 h) is converted to the aldehyde metabolite ABT-971 by recombinant mVAP-1[1].
ABS-752 (125-2500 μM; 15 min) is oxidized by recombinant human VAP-1 with a Km of 674 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:wild-type Hep3B cells, CRISPR-engineered Hep3B GSPT1 G575N (degradation-resistant) cells
-
Concentration:1 nM-50 μM
-
Incubation Time:72 h
-
Result:Potently reduced viability in wild-type Hep3B cells.
Had no effect on the viability of Hep3B GSPT1 G575N cells.
-
Cell Line:Hep3B cells
-
Concentration:10 μM PXS-4728A; 0.1 nM-30 μM ABS-752
-
Incubation Time:1 h (PXS-4728A pre-incubation); 72 h (ABS-752 co-incubation)
-
Result:Pre-treatment with PXS-4728A abolished the viability-reducing activity of ABS-752 in Hep3B cells.
The activity of control compound CC-90009 was unaffected by PXS-4728A pre-treatment.
In Vivo
ABS-752 (100 mg/kg; p.o.; BID; 20-21 days) induces tumor growth inhibition in 80% of tested HCC PDX models, with >50% TGI in four models and complete regression in one model at the 100 mg/kg BID dose[1].
ABS-752 (0.1 mg/kg; single dose) induces significant degradation of GSPT1 and NEK7 in non-human primates at a 0.1 mg/kg dose, with ~80% GSPT1 degradation observed 6 hours post-dose[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NSG mice (female)[1]
-
Dosage:10 mg/kg; 3 mg/kg; 1 mg/kg
-
Administration:p.o.; BID; 14 days
-
Result:Induced strong tumor growth regression, with complete eradication in some animals at 10 mg/kg.
Induced remarkable tumor growth inhibition at 3 mg/kg and 1 mg/kg.
Confirmed strong degradation of GSPT1 in tumors excised 2 and 4 hours post-dose.
-
Animal Model:BALB/c nude mice (female)[1]
-
Dosage:100 mg/kg
-
Administration:p.o.; BID; 20-21 days
-
Result:Inhibited tumor growth in 8/10 models, with tumor growth inhibition (TGI) ranging from 16-100%.
Achieved >50% TGI in four models, including complete tumor regression in the LI6643 model by day 15-16.
Induced strong tumor growth control in the LI0050, LI0752, and LI1069 models.
Chemical Information
-
CAS No. 2761170-84-5
-
Molecular Weight 291.28
-
Formula C14H14FN3O3
-
SMILES
O=C(C(N(CC1=C2C=C(F)C(CN)=C1)C2=O)CC3)NC3=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Liver Cancer Modeling
Liver cancer can be classified into primary liver cancer and secondary liver cancer. Secondary liver cancer is the metastatic liver cancer. Primary liver cancer includes hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC) and fibrolamellar HCC, of which HCC is the most common form, accounting for approximately 90% of primary liver cancers[1]. HCC mouse models include chemical agent-induced models, transplanted tumor models, and genetic engineered models.
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)